NasdaqGS - Nasdaq Real Time Price • USD
CG Oncology, Inc. (CGON)
As of 11:44 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -0.35 | -0.4 | -1.51 | -1.84 |
| Low Estimate | -0.53 | -0.57 | -2.11 | -2.41 |
| High Estimate | -0.14 | -0.2 | -0.72 | -1.11 |
| Year Ago EPS | -- | -- | -15.65 | -1.51 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | 180k | 180k | 1.66M | 8.78M |
| Low Estimate | -- | -- | 500k | -- |
| High Estimate | 530k | 530k | 3.53M | 32.5M |
| Year Ago Sales | -- | -- | 204k | 1.66M |
| Sales Growth (year/est) | -- | -- | 713.70% | 428.90% |
Earnings History
| CURRENCY IN USD | 3/31/2024 | |||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -0.29 |
| EPS Actual | -- | -- | -- | -0.36 |
| Difference | -- | -- | -- | -0.07 |
| Surprise % | -- | -- | -- | -24.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.35 | -0.4 | -1.51 | -1.84 |
| 7 Days Ago | -0.34 | -0.37 | -1.49 | -1.8 |
| 30 Days Ago | -0.32 | -0.35 | -1.44 | -1.7 |
| 60 Days Ago | -0.37 | -0.39 | -1.59 | -1.87 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 2 | 1 |
| Up Last 30 Days | 1 | 1 | 2 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 3 |
Growth Estimates
| CURRENCY IN USD | CGON | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 8.30% |
| Next Qtr. | -- | -- | -- | 11.90% |
| Current Year | 90.40% | -- | -- | 5.60% |
| Next Year | -21.90% | -- | -- | 13.00% |
| Next 5 Years (per annum) | -- | -- | -- | 11.05% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Upgrade | Goldman Sachs: Neutral to Buy | 5/14/2024 |
| Upgrade | Goldman Sachs: Neutral to Buy | 5/13/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/10/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 5/6/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/6/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 5/2/2024 |
Related Tickers
KYTX Kyverna Therapeutics, Inc.
15.37
+5.02%
ANRO Alto Neuroscience, Inc.
13.81
-1.99%
GPCR Structure Therapeutics Inc.
35.73
-0.72%
SLRN Acelyrin, Inc.
4.8550
+3.52%
AVBP ArriVent BioPharma, Inc.
18.71
+4.35%
CABA Cabaletta Bio, Inc.
11.41
+1.29%
RYTM Rhythm Pharmaceuticals, Inc.
40.87
+1.67%
MGX Metagenomi, Inc.
6.74
+2.82%
APGE Apogee Therapeutics, Inc.
54.27
+2.92%
JANX Janux Therapeutics, Inc.
48.68
-2.62%